A phase I study of vinblastine tryptophan ester

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Background:

• Vinblastine tryptophan ester (VTrpE) is a novel vinca alkaloid derivative with demonstrated antitumor potential in preclinical models.
• Vinca alkaloids are established chemotherapeutic agents, but novel derivatives are sought to improve efficacy and reduce toxicity.

Purpose of the Study:

• To evaluate the safety and tolerability of Vinblastine tryptophan ester (VTrpE) in patients with advanced cancer.
• To determine the dose-limiting toxicity and maximum tolerated dose (MTD) of VTrpE.
• To explore preliminary efficacy signals of VTrpE.

Main Methods:

• A Phase I clinical trial was conducted involving twenty patients with advanced cancer.
• VTrpE was administered intravenously (i.v.) over 5 minutes, weekly or bi-weekly, with doses escalating from 2.5 mg/m2 to 35 mg/m2.
• Adverse events, particularly myelosuppression and neurotoxicity, were closely monitored.

Main Results:

• Myelosuppression (leukopenia and thrombocytopenia) was identified as the dose-limiting toxicity, though it was consistently reversible.
• Neurotoxicity was found to be insignificant, a notable difference compared to other vinca alkaloid derivatives.
• Two patients with non-small cell lung cancer experienced disease stabilization.

Conclusions:

• VTrpE is a potentially safe and tolerable agent in advanced cancer patients, with manageable and reversible myelosuppression.
• The observed low incidence of neurotoxicity is promising.
• A dose of 30 mg/m2 per week is recommended for further investigation in Phase II studies, particularly for non-small cell lung cancer.